Vitamin K deficiency in critical ill patients; a prospective observational study
(2019) In Journal of Critical Care 49. p.105-109- Abstract
- Background: Vitamin K is a cofactor for proteins involved in cardiovascular health, bone metabolism and cancer. Measuring uncarboxylated prothrombin, also termed as “protein induced by vitamin K absence or antagonism for factor II (PIVKA-II)”, has been used to assess vitamin K status. High levels may indicate vitamin K deficiency. The aim of this study was to measure PIVKA-II and prothrombin time (PT-INR) in intensive care (ICU) patients and correlate vitamin K status with mortality. Methods: Ninety-five patients admitted to the ICU had blood samples taken near admission and every third day. In addition to PIVKA-II and PT-INR, critical-care severity scores were computed. Results: The median baseline PIVKA-II was 4.97 μg/L compared to the... (More)
- Background: Vitamin K is a cofactor for proteins involved in cardiovascular health, bone metabolism and cancer. Measuring uncarboxylated prothrombin, also termed as “protein induced by vitamin K absence or antagonism for factor II (PIVKA-II)”, has been used to assess vitamin K status. High levels may indicate vitamin K deficiency. The aim of this study was to measure PIVKA-II and prothrombin time (PT-INR) in intensive care (ICU) patients and correlate vitamin K status with mortality. Methods: Ninety-five patients admitted to the ICU had blood samples taken near admission and every third day. In addition to PIVKA-II and PT-INR, critical-care severity scores were computed. Results: The median baseline PIVKA-II was 4.97 μg/L compared to the upper reference of 2.0 μg/L. PIVKA-II further increased at days 3 and 6, (median 7.88 μg/L, p = .047 and median 8.14 μg/L, p = .011) predominantly in cardiac arrest patients (median 21.4 μg/L, day 3). Conclusion: Intensive care patients have increased PIVKA-II levels at admission, which increases during the ICU stay, especially in cardiac arrest patients. There were no correlations between PIVKA-II and PT-INR, SOFA score or mortality. Further studies are needed to determine why PIVKA-II increases and whether high PIVKA-II levels in ICU patients affect long-term mortality or morbidity.
Previous article in issue (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/ee753646-3754-4046-b848-e292db71d46e
- author
- Dahlberg, Sofia LU ; Schurgers, Leon ; Schött, Ulf LU and Kander, Thomas LU
- organization
- publishing date
- 2019
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Journal of Critical Care
- volume
- 49
- article number
- 0883-9441
- pages
- 5 pages
- publisher
- Elsevier
- external identifiers
-
- pmid:30415179
- scopus:85056191765
- pmid:30415179
- ISSN
- 1557-8615
- DOI
- 10.1016/j.jcrc.2018.10.022
- language
- English
- LU publication?
- yes
- id
- ee753646-3754-4046-b848-e292db71d46e
- date added to LUP
- 2018-11-13 16:19:20
- date last changed
- 2024-09-18 06:26:35
@article{ee753646-3754-4046-b848-e292db71d46e, abstract = {{Background: Vitamin K is a cofactor for proteins involved in cardiovascular health, bone metabolism and cancer. Measuring uncarboxylated prothrombin, also termed as “protein induced by vitamin K absence or antagonism for factor II (PIVKA-II)”, has been used to assess vitamin K status. High levels may indicate vitamin K deficiency. The aim of this study was to measure PIVKA-II and prothrombin time (PT-INR) in intensive care (ICU) patients and correlate vitamin K status with mortality. Methods: Ninety-five patients admitted to the ICU had blood samples taken near admission and every third day. In addition to PIVKA-II and PT-INR, critical-care severity scores were computed. Results: The median baseline PIVKA-II was 4.97 μg/L compared to the upper reference of 2.0 μg/L. PIVKA-II further increased at days 3 and 6, (median 7.88 μg/L, p = .047 and median 8.14 μg/L, p = .011) predominantly in cardiac arrest patients (median 21.4 μg/L, day 3). Conclusion: Intensive care patients have increased PIVKA-II levels at admission, which increases during the ICU stay, especially in cardiac arrest patients. There were no correlations between PIVKA-II and PT-INR, SOFA score or mortality. Further studies are needed to determine why PIVKA-II increases and whether high PIVKA-II levels in ICU patients affect long-term mortality or morbidity.<br/><br/> Previous article in issue}}, author = {{Dahlberg, Sofia and Schurgers, Leon and Schött, Ulf and Kander, Thomas}}, issn = {{1557-8615}}, language = {{eng}}, pages = {{105--109}}, publisher = {{Elsevier}}, series = {{Journal of Critical Care}}, title = {{Vitamin K deficiency in critical ill patients; a prospective observational study}}, url = {{http://dx.doi.org/10.1016/j.jcrc.2018.10.022}}, doi = {{10.1016/j.jcrc.2018.10.022}}, volume = {{49}}, year = {{2019}}, }